The Technical Analyst
Sanofi American [SNY]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—General
Sanofi American Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.47% $49.13
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 114 909 mill |
| EPS: | 2.30 |
| P/E: | 21.36 |
| Earnings Date: | Apr 25, 2024 |
| SharesOutstanding: | 2 338.88 mill |
| Avg Daily Volume: | 2.05 mill |
| RATING 2024-04-26 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Buy | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 21.36 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 1.11x |
| Company: PE 21.36 | industry: PE 19.30 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$134.43 (173.62%) $85.30 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 48.38 - 49.88 ( +/- 1.52%) |
| ATR Model: 14 days |
Forecast:
16:00 - $49.21
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $49.21
Forecast 2: 16:00 - $49.21
Forecast 3: 16:00 - $49.21
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $49.13 (-0.47% ) |
| Volume | 4.14 mill |
| Avg. Vol. | 2.05 mill |
| % of Avg. Vol | 202.09 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SNY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $46.38 | N/A | Active |
|---|
SNY
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Latest Press Releases
2024-04-25 01:30:00 - Press Release
Press Release: Sanofi Q1: Robust 7% Sales Growth Driven By Launches, Underpins Full-year Guidance
Sanofi q1: robust 7% sales growth driven by launches, underpins full-year guidance paris, april 25, 2024 sales growth of 6.7% at cer and business eps (1) of €1.78 dupixent sales up 24.9% to €2,835 million, on target to deliver ~€13bn in 2024 pharma launches up 90.5% to €606 million, led by nexviazyme and altuviiio vaccines sales up 5.6%, boosted by beyfortus consumer healthcare (chc) up 9.0%, benefiting from the qunol acquisition in physical and mental wellness and strong digestive wellness performance r&d expenses grew 11.8%, reflecting strategic shift of resources into development sg&a expenses grew 2.9%, less than sales growth business eps(1) of €1.78, down 17.6% reported and 7.4% at cer ifrs eps of €0...
2024-04-23 01:00:00 - Press Release
Press Release: Rilzabrutinib Luna 3 Phase 3 Study Met Primary Endpoint In Immune Thrombocytopenia
Rilzabrutinib luna 3 phase 3 study met primary endpoint in immune thrombocytopenia pivotal data from the first phase 3 study of a btki in immune thrombocytopenia (itp) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with itp regulatory submissions in the us and eu anticipated by year-end rilzabrutinib is one of 12 potential medicines and vaccines in sanofi's robust immunology pipeline and a testament to sanofi's ability to successfully accelerate and build a portfolio of next-generation transformative treatments for immune diseases in addition to itp, rilzabrutinib is being studied across a variety of immune-mediated diseases including asthma, chronic spontaneous urticaria, prurigo nodularis, igg4-related disease and warm autoimmune hemolytic anemia paris, april 23, 2024...
2024-04-17 09:00:00 - Press Release
Cota Announces Strategic Collaboration With Sanofi To Leverage Real-world Data And Ai To Accelerate Cancer Trials
New york--(business wire)--cota, a leader in real-world data (rwd) and analytics for oncology, today announced a strategic collaboration with sanofi to use rwd and artificial intelligence (ai) to increase the speed of oncology trials, including for multiple myeloma. the partnership will be valuable to understand clinical outcomes that may ultimately be beneficial for patients living with cancer. cota's rwd offers critical insights into effective cancer treatment pathways and will provide valuab.
2024-04-17 01:00:00 - Press Release
Press Release: New 48-week Frexalimab Phase 2 Data Support Potential For High Sustained Efficacy In Multiple Sclerosis
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis 96% of participants receiving high-dose intravenous frexalimab had no new gd+ t1 lesions and an annualized relapse rate of 0.04 after 48 weeks sanofi has initiated global phase 3 studies of frexalimab in relapsing ms and non-relapsing secondary progressive ms paris, april 17, 2024. sanofi's cd40l antibody, frexalimab, demonstrated sustained reduction of disease activity and favorable tolerability after nearly one year in participants with relapsing multiple sclerosis.
2024-04-08 12:00:00 - Press Release
Sanofi - Agm 30.04.2024 - Availability Of Preparatory Documents
Combined general meeting of april 30, 2024 availability of preparatory documents the company's shareholders are invited to attend the combined general meeting to be held on thursday april 30, 2024 at 2:30 p.m. (cet) at the palais des congrÈs – amphithÉÂtre bleu – 2, place de la porte maillot – 75017 paris.
Latest News
2024-04-25 12:21:06 - Zacks Investment Research
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Sanofi (SNY) posts first-quarter 2024 results and maintains the earnings growth guidance for the year.
2024-04-25 11:24:10 - Seeking Alpha
Sanofi (SNY) Q1 2024 Earnings Call Transcript
Sanofi (NASDAQ:SNY ) Q1 2024 Earnings Conference Call April 25, 2024 8:30 AM ET Company Participants Paul Hudson - Chief Executive Officer François-Xavier Roger - Chief Financial Officer Houman Ashrafian - Executive Vice President & Head-Research & Development Brian Foard - Executive Vice President & Head-Specialty Care, Sanofi Thomas Triomphe - Executive Vice President-Vaccines, Sanofi Olivier Charmeil - Executive Vice President-General Medicines, Sanofi Conference Call Participants Peter Welford - Jefferies Luisa Hector - Berenberg Graham Parry - BofA Emily Field - Barclays Emmanuel Papadakis - Deutsche bank Seamus Fernandez - Guggenheim Jo Walton - UBS David Risinger - Leerink Gary Steventon - Exane Peter Verdult - Citi Paul Hudson Welcome to the Q1 2024 conference call...
2024-04-25 03:25:00 - WSJ
Sanofi Sales, Profit Beat Forecasts
Sanofi backed its full-year earnings guidance after it reported first-quarter profit ahead of consensus, with sales growth driven by continued strength in anti-inflammatory drug Dupixent and its new drug launches.
2024-04-25 01:32:52 - Reuters
Sanofi Q1 profit slips on generic competition, forex effects
Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent.
2024-04-24 10:21:05 - Zacks Investment Research
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
2024-04-23 13:06:07 - Zacks Investment Research
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.
2024-04-23 13:06:00 - Market Watch
FTC looking to accelerate inquiry into prescription-drug middlemen, chair says
The Federal Trade Commission is working to accelerate its inquiry into the prescription-drug middlemen known as pharmacy-benefit managers, while also expanding its scrutiny of drug patents that can keep prescription prices artificially high, FTC Chair Lina Khan told reporters Tuesday.
2024-04-16 19:09:00 - Market Watch
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
2024-04-09 11:42:00 - Barrons
Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.
The Mag Seven stocks have powered gains in the U.S. market. Now, the hunt is on for an equivalent group of outperformers elsewhere.
2024-04-08 10:08:00 - InvestorPlace
Sanofi Layoffs 2024: What to Know About the Latest SNY Job Cuts
Sanofi (NASDAQ: SNY ) layoffs are in the news Monday after the therapeutic solutions company announced changes to how it will handle research and development going forward. Sanofi wants to focus more on Phase 3 clinical trials and will be reducing its other R&D projects.